| Literature DB >> 34235588 |
Jani Sirkka1, Marita Parviainen2, Henna-Kaisa Jyrkkänen2, Anne M Koivisto3,4,5, Laura Säisänen6,7, Tuomas Rauramaa8, Ville Leinonen2, Nils Danner2.
Abstract
BACKGROUND: Idiopathic normal pressure hydrocephalus (iNPH) is a neurodegenerative disease with a characteristic symptom triad of gait disturbance, cognitive decline, and incontinence. Recently, also dysfunctions in upper limbs have been described in iNPH and reported to improve after shunt surgery. We aim to describe the role of upper limb motor function in the clinical assessment of iNPH patients and its influence on activities of daily living (ADL).Entities:
Keywords: Activities of daily living; Idiopathic normal pressure hydrocephalus; Shunt surgery; Symptoms; Upper limb motor function
Mesh:
Year: 2021 PMID: 34235588 PMCID: PMC8437908 DOI: 10.1007/s00701-021-04909-w
Source DB: PubMed Journal: Acta Neurochir (Wien) ISSN: 0001-6268 Impact factor: 2.216
Fig. 1Flow chart of the study ETV Endoscopic third ventriculostomy, FTD frontotemporal dementia, PD Parkinson’s disease, CERAD Consortium to Establish a Registry for Alzheimer’s Disease
Correlations at baseline, 3-month follow-up, and 12-month follow-up
| Baseline | |||||
|---|---|---|---|---|---|
| 0.613** | 0.470** | 0.435** | 0.705** | 0.322** | |
| 0.522** | 0.413* | 0.586** | 0.217 | ||
| 0.615** | 0.482** | 0.445** | |||
| 0.496** | 0.306* | ||||
| 0.298* | |||||
| 0.657** | 0.615** | 0.471** | 0.566** | 0.495** | |
| 0.657** | 0.500** | 0.530** | 0.407** | ||
| 0.721** | 0.570** | 0.604** | |||
| 0.670** | 0.677** | ||||
| 0.503** | |||||
| 0.568** | 0.409** | 0.482* | 0.563** | 0.569** | |
| 0.404** | 0.223 | 0.334** | 0.358** | ||
| 0.459** | 0.197 | 0.633** | |||
| 0.240 | 0.480** | ||||
| 0.332** | |||||
*p < 0.05 and **p < 0.01
BBT = Box & Block test, GPT = Grooved Pegboard test, TSG = Total score of gait, BI = Barthel’s index
Fig. 2Scores of individual tests at baseline and at follow-ups means and standard deviations of test scores at baseline and at 3- and 12- month follow-ups after shunt surgery
Summary of shunt surgery outcomes
| 36.7 ± 25.7 | 54.5 ± 28.3 | 60.9 ± 30.8 | 85.6% (59/69) | |
| Biopsy+ | 32.2 ± 24.1 | 46.9 ± 23.7 | 53.9 ± 26.8 | 82.8% (24/29) |
| Biopsy- | 41.7 ± 28.4 | 60.3 ± 30.7 | 67.4 ± 32.3 | 84.4% (27/32) |
| 52.8 ± 23.1 | 63.0 ± 16.8 | 61.7 ± 19.2 | 39.1% (27/69) | |
| Biopsy+ | 46.8 ± 26.1 | 60.6 ± 22.0 | 57.6 ± 22.8 | 48.3% (14/29) |
| Biopsy- | 54.8 ± 21.4 | 64.8 ± 12.8 | 63.3 ± 16.3 | 40.6% (13/32) |
| 30.6 ± 23.3 | 40.5 ± 23.7 | 45.3 ± 23.9 | 57.4% (35/61) | |
| Biopsy+ | 30.7 ± 22.7 | 38.9 ± 21.9 | 42.0 ± 21.6 | 48.1% (13/27) |
| Biopsy- | 29.7 ± 23.7 | 42.2 ± 24.4 | 47.9 ± 24.5 | 66.7% (18/27) |
| 39.3 ± 10.1 | 44.6 ± 11.5 | 45.3 ± 10.5 | 72.7% (32/44) | |
| Biopsy+ | 40.2 ± 9.7 | 45.0 ± 10.1 | 45.7 ± 10.2 | 70.8% (17/24) |
| Biopsy- | 37.2 ± 11.3 | 44.4 ± 14.1 | 45.2 ± 12.0 | 81.3% (13/16) |
| 85.6 ± 17.3 | 91.2 ± 13.4 | 92.4 ± 11.2 | 49.3% (34/69) | |
| Biopsy+ | 80.3 ± 22.3 | 90.2 ± 14.5 | 91.7 ± 8.7 | 55.2% (16/29) |
| Biopsy- | 88.8 ± 11.9 | 91.6 ± 14.2 | 93.3 ± 13.2 | 40.6% (13/32) |
| 60.1 ± 11.9 | 63.5 ± 12.5 | 65.7 ± 13.1 | 64.2% (43/67) | |
| Biopsy+ | 58.5 ± 11.5 | 62.1 ± 11.4 | 63.0 ± 13.4 | 64.3% (18/28) |
| Biopsy- | 61.6 ± 13.1 | 64.4 ± 14.2 | 68.6 ± 13.1 | 59.4% (19/31) |
aImprovement of one or more points in the test score at 3-month follow-up
Biopsy+ = subgroup with hyperphosphorylated tau and/or amyloid-beta (Aβ) in cortical brain biopsy
Biopsy- = subgroup without hyperphosphorylated tau or amyloid-beta (Aβ) in cortical brain biopsy
BBT = Box & Block test, GPT = Grooved Pegboard test, TSG = Total score of gait, BI = Barthel’s index
Means and standard deviations of test scores at baseline and at 3- and 12- month follow-ups after shunt surgery
Fig. 3Domains of Barthel’s index in patients with improved total score the grey dotted line represents the mean of baseline values. The black solid line represents the mean of three-month follow-up values. The grey area represents the scale of Barthel’s index, *p < 0.05 and **p < 0.01 (difference between baseline and three-month follow-up)